Literature DB >> 24127478

RSV immunoprophylaxis: does the benefit justify the cost?

H Cody Meissner1, David W Kimberlin.   

Abstract

Keywords:  RSV prophylaxis; asthma; palivizumab; viral respiratory infection

Mesh：

Substances：

Year:  2013        PMID： 24127478     DOI： 10.1542/peds.2013-2449

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  14 in total

1.  Respiratory syncytial virus and palivizumab: Where are we in 2014?

Authors:  Joan Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

2.  Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines.

Authors:  Carrie L Byington; Flor M Munoz
Journal:  Pediatrics       Date:  2016-07-18       Impact factor: 7.124

3.  Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.

Authors:  Almut G Winterstein; Yoonyoung Choi; H Cody Meissner
Journal:  JAMA Pediatr       Date:  2018-02-01       Impact factor: 16.193

4.  Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.

Authors:  Stanislav O Fedechkin; Natasha L George; Ana M Nuñez Castrejon; Joshua R Dillen; Lawrence M Kauvar; Rebecca M DuBois
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

5.  Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?

Authors:  Marco Aurélio P Sáfadi
Journal:  Rev Paul Pediatr       Date:  2014-06

6.  Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Authors:  Alexander Gutfraind; Alison P Galvani; Lauren Ancel Meyers
Journal:  JAMA Pediatr       Date:  2015-04       Impact factor: 16.193

Review 7.  Recent evidence on the management of bronchiolitis.

Authors:  Alan R Schroeder; Jonathan M Mansbach
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

8.  Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.

Authors:  Zhiwu Sun; Qian Wang; Ran Jia; Shuai Xia; Yuan Li; Qi Liu; Wei Xu; Jin Xu; Lanying Du; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2015-02-16       Impact factor: 5.048

9.  Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.

Authors:  K K McLaurin; A M Farr; S W Wade; D R Diakun; D L Stewart
Journal:  J Perinatol       Date:  2016-08-04       Impact factor: 2.521

Review 10.  Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.

Authors:  Ralph A Tripp; Ultan F Power; Peter J M Openshaw; Lawrence M Kauvar
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.